Asitri Dashboard

Search Clinical Trials

The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.

Saved Searches

Choose Search
Basic Search
Targeted Search

Clinical Trials Search Results

Search History:
Count: 95
Selected: 0
NCT IDTitle
NCT02741388A Phase Ib Study of Oral Selinexor in Adult Patients With Relapsed/Refractory B-cell Lymphoma Receiving R-DHAOx or R-GDP
NCT03071276Selinexor in Combination With Fludarabine and Cytarabine in Patients With Refractory or Relapsed Acute Myeloid Leukemia
NCT03042819Study of Selinexor and Doxorubicin in Advanced Soft Tissue Sarcomas
NCT04562389Study of Selinexor in Combination With Ruxolitinib in Myelofibrosis
NCT03095612Phase 1/2 Trial of Selinexor (KPT-330) With Docetaxel for Non-small Cell Lung Cancer (NSCLC)
NCT01986348Study Evaluating the Efficacy and Safety of Selinexor (KPT-330) in Participants With Recurrent Gliomas
NCT02389543Study of Selinexor (KPT- 330), Lenalidomide, & Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients
NCT02384850Phase 1 Trial To Evaluate mFOLFOX6 With Selinexor In Patients With Metastatic Colorectal Cancer
NCT05980806A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia
NCT04421378A Study of Selinexor in Combination With Standard of Care Therapy for Newly Diagnosed or Recurrent Glioblastoma
NCT02088541Selinexor (KPT-330) in Older Patients With Relapsed AML
NCT02471911KPT-330 Plus RICE for Relapsed/Refractory Aggressive B-Cell Lymphoma
NCT02780609Selinexor Plus High-Dose Melphalan (HDM) Before Autologous Hematopoietic Cell Transplantation for Multiple Myeloma
NCT02249091A Phase II Study of Selinexor Plus Cytarabine and Idarubicin in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML)
NCT02367690Study of Safety, Tolerability, and Pharmacokinetics of Topical Selinexor (KPT-330) Diabetic Foot Ulcer (DFU) Patients
NCT05530421Selinexor, Venetoclax, and Dexamethasone (XVenD) in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma
NCT05028348A Study of Combination of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Subject With Previously Treated Multiple Myeloma
NCT02402764Phase 2 Trial of Selinexor (KPT-330) for Metastatic Triple Negative Breast Cancer (TNBC)
NCT04661137A Study of Selinexor, in Combination With Carfilzomib, Daratumumab or Pomalidomide in Patients With Multiple Myeloma
NCT01896505A Phase I Trial to Assess the Effects of Food and Formulation on PK of KPT-330 in Patients With Sarcoma
NCT04519476Selinexor Treatment for Multiple Myeloma Patients Who Are Refractory to Lenalidomide-containing Therapy.
NCT02436707Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma
NCT05170789Elotuzumab, Selinexor, and Dexamethasone for Relapsed Refractory Multiple Myeloma
NCT02025985Study of KPT-330 (Selinexor) in Female Patients With Advanced Gynaecologic Malignancies
NCT04562870A Study to Evaluate Single Agent Selinexor Versus Physician's Choice in Participants With Previously Treated Myelofibrosis
NCT04442022A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
NCT04843579Treatment of Selinexor in Combination With Clarithromycin, Pomalidomide and Dexamethasone for Relapsed Refractory Multiple Myeloma Patients
NCT02299518Selinexor and Chemotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
NCT02137356Selinexor Combined With Standard Chemoradiation as Neoadjuvant Treatment in Locally Advanced Rectal Cancer
NCT04256707Relative Bioavailability/Bioequivalence of Different Formulations of Selinexor, the Impact of Hepatic Impairment on Selinexor Pharmacokinetics, Tolerability and Antitumor Activity of Selinexor Combination Treatment
NCT03732703Myeloma-Developing Regimens Using Genomics (MyDRUG)
NCT02146833SHIP (Selinexor in Hormone Insensitive Prostate Cancer)
NCT02628704Selinexor, Carfilzomib, and Dexamethasone Versus Placebo, Carfilzomib, and Dexamethasone in Multiple Myeloma
NCT03110562Bortezomib, Selinexor, and Dexamethasone in Patients With Multiple Myeloma
NCT02314247Efficacy and Safety Study of Selinexor in Relapsed or Refractory Peripheral T-cell Lymphoma or Cutaneous T-cell Lymphoma
NCT01607892Safety Study of the Selective Inhibitor of Nuclear Export (SINE) KPT-330 in Patients With Advanced Hematological Cancer
NCT02536495Selinexor and Docetaxel in Treating Patients With Recurrent or Metastatic Squamous Cell Lung Cancer
NCT02351505Selinexor in Treating Patients With Relapsed Small Cell Lung Cancer
NCT05983276Decitabine and Selinexor in Combination to Reverse Drug Resistance With Standard Chemotherapy in Ovarian Cancer
NCT07200102Selinexor Maintenance Post CAR-T Cell Therapy for Multiple Myeloma
NCT02120222Evaluating SINE KPT-330 in Treating Patients With Melanoma That Cannot Be Removed By Surgery
NCT06399640Eltanexor and Venetoclax in Relapsed or Refractory Myelodysplastic Syndrome and Acute Myeloid Leukemia
NCT02606461Selinexor in Advanced Liposarcoma
NCT02343042Selinexor and Backbone Treatments of Multiple Myeloma Patients
NCT05820763Selinexor and Lenalidomide for Consolidation and Maintenance Treatment in Multiple Myeloma Post-transplant
NCT04854434A Study to Evaluate the Safety and Efficacy of Selinexor With or Without Pembrolizumab Versus Standard of Care in Previously Treated Metastatic Colorectal Cancer With RAS Mutations
NCT04607772Study of Selinexor in Combination With Backbone Treatments or Novel Therapies In Participants With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL)
NCT04914845KPT-9274 in Patients With Relapsed and Refractory Acute Myeloid Leukemia
NCT02078349Phase I Study of KPT330 in Asian Patients
NCT05611931Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma